French pharmaceutical group Sanofi SA (SAN.FR) said Wednesday it signed an agreement with Medco Health Solutions Inc (MHS) and its unit United BioSource Corp., or UBC, to better leverage the real-world evidence generated during product development and throughout the product lifecycle in order to improve the overall quality of patient care.

MAIN FACTS:

- Under the terms of this multi-year agreement, Medco and UBC will provide real-world input and comparative data into product development strategy.

- This agreement will allow Sanofi to define the relative value for products early in development, by more precisely identifying patient populations in which drugs are most effective.

- It will also enable Sanofi to maximize the full value potential of R&D innovation through early alignment of patient population assessments, payer and medical needs. The objective is to develop integrated solutions for patients by implementing novel care models and to improve adherence and patient outcomes.

- Sanofi didn't release any financial details on the agreement with Medco.

- By Paris Bureau, Dow Jones Newswires; +331-4017-1740; inti.landauro@dowjones.com

Medco (NYSE:MHS)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Medco Charts.
Medco (NYSE:MHS)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Medco Charts.